Introduction
There is a considerable body of evidence demonstrating that the regular consumption of n-3 polyunsaturated fatty acids (PUFA) as fish, fish oil, or vegetable oil, is associated with significant health benefits in cardiovascular disease (Hu et al, 2001 ) and rheumatoid arthritis . Fish oil contains the long-chain n-3 PUFA (LC n-3 PUFA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The n-3 containing vegetable oils, primarily flax, canola, and soy, contain the shorter chain n-3 PUFA, a-linolenic acid (ALA).
Increased consumption of n-3 fatty acids has been recommended by health authorities in Canada (Scientific Review Committee, 1990 ) and the United Kingdom (The British Nutrition Foundation, 1992) , and daily intakes of about 200-400 mg of LC n-3 PUFA have been recommended in Europe and the US (de Deckere et al, 1998; Simopoulos et al, 2000) .
Despite this, Western societies consume little fish, and increasing consumption to recommended levels would involve major alterations in dietary habits. To date, the only alternative strategy has been a regular consumption of encapsulated fish oil, an approach that is unsuitable over a prolonged period for many people. An alternative strategy for enhancing the long-term increase in n-3 PUFA intake may be to provide a wide range of commercial food products and ingredients fortified with fish oil or ALA, which can be incorporated into an existing diet. In this study, we have provided a number of novel foods fortified with fish oil, and products high in ALA, and allowed the subjects to incorporate them into their domestic food preparation in accordance with their own tastes and preferences. The aims were to examine intakes of individual n-3 PUFA, together with the dietary preferences of the subjects and the proportion of LC n-3 PUFA which were achieved in blood and tissue by this approach.
Materials and methods

Subject selection
In all, 16 healthy male subjects were recruited through advertisements for volunteers to participate in dietary intervention studies. The details of the study were explained and written, informed consent was obtained from all participants. The study was approved by the Research Ethics Committee of the Royal Adelaide Hospital.
Diets
Subjects were provided with a range of products designed to increase their intake of n-3 PUFA, and decrease their intake of n-6 PUFA. This was achieved by providing a range of products (a) rich in ALA, (b) rich in EPA and DHA, and (c) olive oil-based products high in monounsaturated fatty acids to replace linoleic acid (LA) in the background diet. Products provided which were high in ALA were canola oil (Meadow Lea Foods Pty Ltd, Sydney, Australia), and flaxseed-based products (stabilized flaxseed meal, and Alena Energy Drink, both provided by ENRECO, Manitowoc, WI, USA). Foods which were high in EPA and DHA were fresh fish (mullet and deep sea bream), canned fish (pink salmon and sardines; Safcol Holdings, Adelaide, Australia), and a number of items fortified with fish oil (Ropufa-30; Roche Vitamins, Sydney, Australia), including sausages, luncheon meat (Conroys Smallgoods, Adelaide, Australia), long-life milk (Pauls Ltd, Brisbane, Australia), olive oil-based margarine spread (Meadow Lea Foods Pty Ltd, Sydney, Australia), and French onion dip. Subjects were also provided with olive oil-based salad dressing and mayonnaise (Meadow Lea Foods Pty Ltd, Sydney, Australia), and muffin mix (White Wings Foods, Sydney, Australia) from which shortening was omitted, so that canola oil could be added during preparation. The fatty acid composition of the n-3 enriched foods provided to the participants is detailed in Table 1 . The fish oil was fortified with 1000 p.p.m. dl-a-tocopherol.
Subjects were not asked to consume set quantities of each food, but rather were instructed to incorporate these foods into their normal diet in desired quantities, and advice was provided on using the novel foodstuffs. Foods were provided in quantities sufficient for the whole family, to avoid separate meal preparation being required for participants.
To maximize the incorporation of n-3 PUFA, dietary advice was provided on reducing their intake of foods which are high in LA, for example, nuts, cooking oils, and commercial food products high in LA-rich vegetable oils.
Subjects were instructed to complete weighed food records for 3 days/week (2 days during the week, and 1 day on the weekend) for 2 weeks prior to the dietary intervention period to provide data on baseline fatty acid intakes, and for the 4-week dietary intervention period. Diet diaries were analyzed using the Diet-1 software package (v 4.20, Xyris Software, Brisbane, Australia), which is based on the Australian Nutrient Data Table NUTTAB95 (Australian Government Publishing Service, Canberra, Australia), modified to include the fatty acid content of Australian foods and ingredients, as well as the novel fish-oil fortified foods. Participants were provided with digital kitchen scales (2 g increments).
Analytic methods
Fasting peripheral blood was sampled at À2, 0, 2, and 4 weeks, separated into plasma, mononuclear cell and platelet fractions, and fatty acids were extracted and analyzed as described previously (Mantzioris et al, 2000) . Briefly, 20 ml of peripheral blood was added to 4 ml of 4.5% EDTA in water, and 4 ml of 6% dextran in normal saline (pH 7.0), and incubated in a water bath at 371C for 30 min to allow the erythrocytes to sediment under gravity. The remaining leukocyte and platelet-rich plasma was loaded onto a Ficoll-Paque gradient (Lymphoprep, Nycomed Pharma, Increasing consumption of n-3 fats using novel foods RG Metcalf et al Oslo, density 1.077 kg/l), and centrifuged at 110 Â g for 10 min at 251C. The resulting top layer containing the platelet-rich plasma was removed into a separate tube and was centrifuged at 200 Â g for 25 min. The plasma fraction was removed from the platelet pellet and stored at À201C. The platelet pellet was resuspended in 4 ml of 0.2% saline for 30 s to lyse any remaining erythrocytes, followed by addition of 4 ml of 1.6% saline and centrifuged at 320 Â g for 10 min and resuspended in 1.5 ml of normal saline. The remaining density gradient containing the mononuclear and polymorphonuclear cells was centrifuged at 200 Â g for 25 min. The mononuclear cell layer was removed from the gradient interface, washed once with PBS, centrifuged at 320 Â g for 10 min and resuspended in 1.5 ml of normal saline. The remainder of the density gradient containing the neutrophils was discarded. Total lipids were extracted by vortex mixing the cell fraction with 2 ml of methanol, followed by 4 ml of chloroform, and centrifuging at 320 Â g for 10 min. The chloroform layer was removed and evaporated to dryness in a centrifugal Speed Vac Concentrator (Savant Instruments Inc, Farmingdale, NY, USA). Samples were then resuspended in 2 ml of chloroform/methanol (9:1 v/v) and stored at À201C.
Phospholipid fractions were separated from total lipid extracts by activated silica thin layer chromatography developed in petroleum spirit/acetone (3:1 v/v), and transesterified by methanolysis (1% H 2 SO 4 in methanol at 701C for 3 h). The resultant fatty acid methyl esters were separated and quantified by GLC (Hewlett-Packard 5890, HewlettPackard, Palo Alto, CA, USA), with identification based on retention times of authentic standards (NuCheck Prep, Elysian, MN, USA).
Statistics
Differences in dietary intakes and blood fatty acids between visits were compared by repeated measures analysis of variance (ANOVA), with post hoc analysis by Newman-Keuls multiple comparisons method. Statistical analyses were performed using Winks v. 4.5 Professional Edition (TexaSoft, Cedar Hill, TX, USA).
Results
Subjects
In all, 16 participants completed the study, and there were no withdrawals. The participants had a mean age of 39.274.4 y, and a mean body mass index (BMI) of 25.872.6 kg/m 2 at the commencement of the study. There was a small but significant increase in BMI during the first 2-week dietary intervention period to 26.072.6 kg/m 2 (Po0.01), followed by a nonsignificant increase to 26.272.6 kg/m 2 at the end of 4 weeks of dietary intervention.
Dietary intakes
Macronutrient intakes were estimated from the diet diaries, and are provided in Table 2 . There was a significant increase in the amount of protein in the diet during the first dietary intervention period compared to baseline, both in terms of grams per day, and as percentage of dietary energy. There was no further increase during the second dietary intervention period. There were no changes in total fat or carbohydrate intake during the study. Fatty acids. There were significant increases in the intake of oleic acid, ALA, EPA, and DHA, and a significant decrease in LA intake during the dietary intervention period compared to baseline intakes (Table 3) . The contribution of each provided food item to the total n-3 intake is provided in Table 4 . All subjects consumed the cooking oil, flaxseed products and margarine spread at some time during the study period, while only 50% of subjects ate sardines on at least one of the recording days. Fish (canned and fresh) provided the largest contribution to the LC n-3 PUFA intake, with canned salmon providing about 24% of the EPA and 34% of the DHA intakes of those eating salmon.
Fresh fish (deep sea bream and mullet) together provided about 19% each of the EPA and DHA intake of those subjects that ate fresh fish.
Flaxseed products provided about 57% of the total ALA intake, with canola cooking oil providing a further 19%. The margarine spread was primarily olive oil based, and therefore contributed only a very small proportion of the ALA intake. Of the novel fish oil enriched products, the margarine spread was the most popular, with all subjects consuming it. The mean intake was 18 g/day, which provided about 160 mg/day of EPA þ DHA, which represented about 10% of the total EPA þ DHA in the diet. Milk The mean quantity and percentage of the n-3 PUFA contributed by the food in only those subjects consuming that particular food.
Increasing consumption of n-3 fats using novel foods RG Metcalf et al was the second most popular food, being consumed by 15/16 subjects, with the mean intake amongst consumers of about 275 ml/day. This contributed about 200 mg/day (12.8% of total intake) of EPA þ DHA. The least popular of the novel foods were the luncheon meat and the dip, with only 9/16 subjects consuming these items on any recording day. Among consumers, the luncheon meat and dip contributed a mean daily intake of EPA þ DHA of 122 and 82 mg, respectively. However, the sausages provided a similar contribution to EPA þ DHA intake as that of fresh fish.
Plasma and cellular fatty acids
There were significant decreases in the proportions of n-6 PUFAs in plasma phospholipids following 2 weeks of dietary modification with falls of 15, 9, and 15% for LA, AA and total n-6, respectively (Table 5 ). There were no further decreases recorded following a further 2 weeks of dietary modification. There were significant increases in the proportion of ALA (56%), EPA (174%), DHA (80%), and total n-3 (79%) in the plasma phospholipid fraction at 2 weeks, with a small decrease in the ALA content being the only significant change between 2 and 4 weeks. As with plasma phospholipids, there were significant decreases in the proportions of n-6 PUFAs in mononuclear cell phospholipids after 2 weeks of diet modification, with falls of 5, 11, and 12% for LA, AA and total n-6, respectively (Table 6 ). During the final 2 weeks of dietary modification, the LA content rose back to those recorded at baseline. The proportions of EPA, DHA, and total n-3 PUFA increased significantly during the first 2 weeks, with rises of 173, 57, and 38%, respectively. All three continued to increase during the final 2 weeks, with further rises of 15, 12, and 8%, respectively.
Changes in platelet phospholipid fatty acids were qualitatively similar to those with mononuclear cells (Table 7) . There were significant decreases of 10, 3, and 6% for LA, AA and total n-6 PUFA, respectively, during the first 2 weeks of dietary intervention, with further significant falls of 3 and 2% for AA and total n-6 PUFA, respectively, during the second period, whereas LA increased during this period by 5%. The proportions of ALA, EPA, DHA, and total n-3 PUFA increased significantly during the first 2 weeks, with rises of 63, 166, 70, and 49%, respectively. EPA, DHA and total n-3 PUFA continued to increase during the final 2 weeks, with further rises of 10, 10, and 7%, respectively.
The correlation coefficients (r) between platelet and mononuclear cell EPA, DHA, and total n-3 PUFA for all time points were 0.99, 0.95, and 0.94, respectively. Similarly, the correlation coefficients between plasma phospholipid and mononuclear cell EPA, DHA, and total n-3 PUFA were 0.94, 0.92, and 0.91, respectively, while for plasma phospholipid and platelets, the correlation coefficients were 0.93, 0.87, and 0.88, respectively.
Discussion
In this study, we have demonstrated that by providing subjects with everyday food items fortified with fish oil, LC n-3 PUFA intakes of the order of 200-400 mg/day recommended for community-wide intakes (Scientific Review Committee, 1990; The British Nutrition Foundation, 1992; de Deckere et al, 1998; Simopoulos et al, 2000) and intakes of about 1 g/day as recommended for people with documented CHD (Kris-Etherton et al, 2002) are readily achievable. Lovegrove et al (1997) fortified some everyday items with fish oil such as bread and spread, along with a number of sweet foods, including biscuits, cake, ice cream, and milkshake powder, and used a portion exchange system with the aim of achieving a daily intake of 1.8 g EPA þ DHA. Likewise, Mantzioris et al (2000) used a similar dietary approach with fish-oil-fortified savoury products like sausages and dip, and had a large emphasis on ingestion of fresh fish, and set a target EPA content in mononuclear cell phospholipids of 1.5% of total fatty acids. Subjects achieved mean daily intakes of EPA þ DHA of 1.4 and 1.8 g, respectively. However, in both studies, the investigators gave no indication of the popularity of each food item, or the contribution of each food item to the total LC n-3 PUFA intake.
In the present study, we have used similar foods to those used by Mantzioris et al (2000) with the addition of fish-oilfortified margarine spread and long-life milk. This is the first study to examine the food preferences of the subjects, and the contribution of the individual food items to the overall intakes of EPA and DHA. A combination of the mean daily intakes of margarine spread (18 g/day providing 156 mg of EPA þ DHA), milk (285 ml/day providing 200 mg of EPA þ DHA), sausages (4/week providing an average daily intake of about 250 mg EPA þ DHA), 15 g of dip provided about 120 mg of EPA þ DHA and 32 g of luncheon meat providing about 80 mg of EPA þ DHA gives a total daily intake of about 800 mg. This approaches the mean daily intake of 1 g of EPA þ DHA as recommended for people with documented CHD (Kris-Etherton et al, 2002) .
A number of other studies have examined the effects of incorporating fish-oil enriched products in the diet. Saldeen et al (1998) added fish oil to bread and instructed subjects to consume 125 g/day, which provided a daily LC n-3 PUFA intake of 300 mg. They observed increases in plasma phospholipid EPA and DHA of 32 and 18%, respectively, after 2 weeks. When 500 ml/day of fish oil fortified, partially fat reduced milk, also providing 300 mg EPA þ DHA daily, was consumed for 6 weeks, plasma phospholipid EPA and DHA both increased by 31% (Visioli et al, 2000) . Wallace et al (2000) used microencapsulated fish oil incorporated into bread, biscuits and soup to achieve a daily intake of 900 mg of LC n-3 PUFA/day, and reported that subjects expressed a preference for the bread as it was easier to incorporate into the normal diet. Increases in platelet EPA and DHA of 82 and 44%, respectively, were observed after 4 weeks. In the current study, both mononuclear cell and platelet EPA increased by about 170% in the first 2 weeks, with further small but significant increases during the next 2 weeks, however, only two subjects achieved mononuclear cell EPA levels of 1.5% of total fatty as proposed by Mantzioris et al (2000) as a potential target for anti-inflammatory benefits.
A major hurdle to the generalized worldwide enrichment of foodstuffs with fish oil is the limited availability of fish stocks, and the possibility of decreased supply and increased cost of fish oil (Naylor et al, 2000) . The use of renewable terrestrial sources of n-3 PUFA therefore becomes important. While the efficiency of the conversion of ALA to the longer chain n-3 metabolites remains controversial (Gerster, 1998) , there is clearly an indication for promoting an increase in ALA consumption. Increasing ALA consumption to about 9 g/day through the addition of flaxseed to the diet as margarine spread (Mantzioris et al, 1994) or baked in muffins (Cunnane et al, 1995) significantly increased plasma phospholipid proportions of EPA and DPA. Previous research suggests that minimizing the background intake of LA (the predominant n-6 PUFA) is important in maximizing the uptake of LC n-3 PUFA (Cleland et al, 1992) and the conversion of ALA to EPA (Emken et al, 1994) .
Irrespective of elevation in tissue LC n-3 PUFA, ALA consumption itself has been associated with reduced risk of cardiovascular disease. The Health Professionals Follow-up Study (Ascherio et al, 1996) found a 59% reduction in the risk of MI associated with an increase in ALA consumption of 1% of dietary energy. In a 10 MJ diet, a 1% increase in energy equates to 2.7 g ALA, an amount found in about two tablespoons of ground flaxseed meal. A similar quantity of ALA supplementation (2.9 g/day in the form of mustard oil) was given in the Indian Infarct Survival study (Singh et al, 1997) , a secondary prevention study among survivors of suspected acute MI, which found a significant reduction in the risk of total cardiac events and nonfatal MI compared to placebo (28 vs 34.7% and 15.0 vs 25.4%, respectively) after 12 months of follow-up.
Significant reductions in risk of all-cause mortality (31%) and cardiovascular disease mortality (37%) were associated with the highest quintile of ALA consumption compared to the lowest quintiles (mean intakes, 2.80 and 0.87 g/day, respectively) in the MRFIT Study (Dolecek & Granditis, 1991) , while in the Nurse's Health Study (Hu et al, 1999) , there was a 45% reduction in coronary heart disease mortality from the lowest (0.71 g/day) to the highest (1.36 g/day) quintiles of ALA consumption. The Lyon Diet Heart Study (de Lorgeril et al, 1994) found a significant reduction in risk of both cardiac death and nonfatal MI associated with increased consumption of ALA.
In the study presented here, subjects consumed a mean intake of 4.1 g ALA/day, of which over 50% was derived from flaxseed meal. In this study, the margarine spread was olive oil-based, whereas had a canola oil-based margarine spread been used, the mean ALA intake would have increased by about 1 g/day.
Having a wide range of n-3 PUFA-enriched products enables those people who do not eat fish habitually or who never eat fish, to benefit from the increased intake of n-3 PUFA without radical modification of their normal dietary habits. Increased daily consumption of n-3 PUFA from an early age may help prevent the onset of a variety of so-called 'lifestyle' diseases, such as atherosclerosis, diabetes, essential hypertension, and obesity (Das, 2000) , thereby reducing the need for high therapeutic doses of n-3 PUFA, which have been the hallmark of most intervention studies to date.
